Charles Lowenstein

CHARLIE LOWENSTEIN, M.D., assumed his role as the chief of the Johns Hopkins Division of Cardiology on January 6, 2020.  Dr. Lowenstein obtained his M.D. at the Harvard Medical School. He completed his medical residency at the Massachusetts General Hospital and his cardiology fellowship at the Johns Hopkins University School of Medicine, prior to joining the faculty of the Johns Hopkins Division of Cardiology as an assistant professor in 1993. Over the course of the next sixteen years, Dr. Lowenstein was promoted to associate professor and professor of medicine. He left Johns Hopkins in 2009 to assume the role of chief of cardiology at the University of Rochester Medical Center, where he also served as professor of medicine and director of the Cardiovascular Research Institute at the University of Rochester School of Medicine and Dentistry. He is board certified in internal medicine and cardiovascular disease.

As chief of cardiology at the University of Rochester, he was responsible for overseeing all clinical and translational research in the division. In his role as director of the Aab Cardiovascular Research Institute, he oversaw research, mentorship, recruitment, finances, and administration of their cardiovascular basic science programs. Dr. Lowenstein’s own research is focused on vascular biology, with a focus on vascular inflammation and thrombosis. He is the current recipient of an NIH R01 grant for his work on population genomic variation, functional biology, and the risk of venous thrombosis.  He has received over 33 major grants in the course of his career, including four previous NIH R01 Grants for which he was the principal investigator.

Dr. Lowenstein has served on the NIH Atherosclerosis and Inflammation Cardiovascular Sciences study section. He is a member of the Sarnoff Cardiovascular Research Foundation, an organization that funds medical student research. Dr. Lowenstein’s past awards include the Peter Dolphin Award from Pfizer, the Sir William Osler Young Investigator Award, and the Young Investigators Conference on Atherosclerosis Award from Merck.